

ASX RELEASE

22 April 2016

Results of General Meeting

MMJ PhytoTech Limited (ASX:MMJ) today held a General Meeting at the Offices of BDO, 38 Station Street, Subiaco WA 6008.

All resolutions were passed on a show of hands.

In accordance with section 251AA of the Corporations Act, proxy votes exercisable by all proxies validly appointed were;

Resolution	For	Discretionary	Abstain	Against
1. Ratification of Placement	3,499,860	240,549	30,000	450,630
2. Issue of Options Pursuant to Placement	3,401,194	240,549	51,000	528,296
3. Issue of Options to Advisors	3,359,026	240,549	95,668	525,796

For more information please contact

Erlyn Dale

Company Secretary

+61 8 9389 3150

info@mmjphytotech.com.au

ASX RELEASE

About MMJ PhytoTech Limited

MMJ PhytoTech Limited is a vertically integrated medical cannabis (MC) company operating globally. The Company aims to commercialise MC and a growing portfolio of sophisticated MC delivery technologies to the rapidly growing international market for legal medical cannabis. The Company operates under three main subsidiaries with operations across the entire Medical Cannabis value chain, encompassing the Company's "Farm to Pharma" strategy.

United Greeneries is MMJ's Canadian-based MC cultivation subsidiary. UG has two facilities with pending MMPR applications, the Duncan Facility on Vancouver Island, BC, and Lucky Lake located in SK. The Company's flagship MMPR applicant is the Duncan Facility which has received notice from Health Canada of a Pre-License Inspection commencing February 1 2016. The Duncan Facility is a state-of-the-art MC cultivation facility with a capacity of up to 1000 KG of dried MC production per year.

Satipharm is the company's pharmaceutical processing subsidiary with global subsidiaries for regional operation (Switzerland, Australia and Canada). Satipharm is involved with the extraction, refinement & sales of derivative MC products contained in exclusive sophisticated delivery technologies such as special microgel capsules which dramatically increase bioavailability of fat soluble Cannabinoids or a unique new process of creating water soluble solutions from fat soluble cannabinoids.

Through its **PhytoTech Therapeutics** subsidiary in Israel the Company conducts R&D for the larger group and performs clinical trials on various quick-to-market delivery technologies etc.

<http://www.mmjphytotech.com.au>